Sulzer Cervical Fusion System Gains Panel Nod; Firm May Be First To Market
This article was originally published in The Gray Sheet
Executive Summary
Sulzer Spine-Tech should perform a sensitivity analysis on existing data to make a stronger case that patients who dropped out of the study's control group did not bias conclusions in favor of the firm's BAK/C cervical interbody fusion system, FDA's Orthopedic and Rehabilitation Devices panel recommended.